- 1 Transcriptome-Wide Association Analysis Identifies Novel Candidate Susceptibility Genes for
- 2 Prostate-Specific Antigen Levels in Men Without Prostate Cancer
- 3 **Author List:**
- Dorothy M. Chen¹*, Ruocheng Dong²*, Linda Kachuri^{2,3}, Thomas Hoffmann^{1,4}, Yu Jiang¹, 4
- Sonja I. Berndt⁵, John P. Shelley⁶, Kerry R. Schaffer^{7,12}, Mitchell J. Machiela⁵, Neal D. 5
- Freedman⁵, Wen-Yi Huang⁵, Shengchao A. Li⁵, Hans Lilja^{8,9}, Stephen K. Van Den Eeden¹⁰, 6
- Stephen Chanock⁵, Christopher A. Haiman^{11,12}, David V. Conti^{11,12}, Robert J. Klein¹³, Jonathan 7
- D. Moslev¹⁴, John S. Witte^{1,2,15}†, Rebecca E. Graff ¹† 8
- 9 **Affiliations:**
- 10 1) Department of Epidemiology and Biostatistics, University of California, San Francisco, San
- 11 Francisco, CA, 94158, USA
- 12 2) Department of Epidemiology and Population Health, Stanford University, Stanford, CA,
- 13 94305, USA
- 14 3) Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA
- 15 4) Institute for Human Genetics, University of California San Francisco, San Francisco, CA,
- 16 94143, USA
- 17 5) Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD,
- 18 20814, USA
- 19 6) Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN,
- 20 37232, USA
- 21 7) Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN,
- 22 37232, USA

- 8) Departments of Pathology and Laboratory Medicine, Surgery, Medicine, Memorial Sloan
- 24 Kettering Cancer Center, New York, NY, 10065, USA
- 9) Department of Translational Medicine, Lund University, Malmö, 21428, Sweden
- 26 10) Division of Research, Kaiser Permanente Northern California, Oakland, CA, 94612, USA
- 27 11) Center for Genetic Epidemiology, Department of Population and Preventive Health Sciences,
- 28 Keck School of Medicine, University of Southern California, Los Angeles, CA, 90032, USA
- 29 12) Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern
- 30 California, Los Angeles, CA, 90033, USA
- 31 13) Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
- 32 New York, NY, 10029, USA
- 33 14) Departments of Internal Medicine and Biomedical Informatics, Vanderbilt University
- 34 Medical Center, Nashville, TN, 37232, USA
- 35 15) Departments of Biomedical Data Science and Genetics (by courtesy), Stanford University,
- 36 Stanford, CA, 94305, USA

- * These authors contributed equally to this work
- † These authors jointly supervised this work
- * Correspondence: jswitte@stanford.edu and Rebecca.Graff@ucsf.edu

Abstract

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

Deciphering the genetic basis of prostate-specific antigen (PSA) levels may improve their utility to screen for prostate cancer (PCa). We thus conducted a transcriptome-wide association study (TWAS) of PSA levels using genome-wide summary statistics from 95,768 PCa-free men, the MetaXcan framework, and gene prediction models trained in Genotype-Tissue Expression (GTEx) project data. Tissue-specific analyses identified 41 statistically significant (p < 0.05/12,192 = 4.10e-6) associations in whole blood and 39 statistically significant (p < 0.05/13,844 = 3.61e-6) associations in prostate tissue, with 18 genes associated in both tissues. Cross-tissue analyses that combined associations across 45 tissues identified 155 genes that were statistically significantly (p < 0.05/22,249 = 2.25e-6) associated with PSA levels. Based on conditional analyses that assessed whether TWAS associations were attributable to a lead GWAS variant, we found 20 novel genes (11 single-tissue, 9 cross-tissue) that were associated with PSA levels in the TWAS. Of these novel genes, five showed evidence of colocalization (colocalization probability > 0.5): EXOSC9, CCNA2, HIST1H2BN, RP11-182L21.6, and RP11-327J17.2. Six of the 20 novel genes are not known to impact PCa risk. These findings yield new hypotheses for genetic factors underlying PSA levels that should be further explored toward improving our understanding of PSA biology.

Introduction

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Prostate-specific antigen (PSA) is a serine protease of the human tissue kallikrein-related (KLK) peptidase family. Serum levels are commonly used as a biomarker for detection, monitoring, and risk stratification of prostate cancer (PCa). ¹⁻³ The process by which a small portion of the highly abundant PSA in the prostate is released into the blood and elevated in men prostate cancer is incompletely understood, but disruption of the prostate gland architecture by neoplastic transformation has been speculated as a possible mechanism. ^{1,3,4} PSA levels can additionally be influenced by age, race, body mass index (BMI), infection, prostate volume, benign prostate hyperplasia (BPH), and germline genetics.^{5,6} PSA screening has been used for over 25 years for the detection of PCa, which is the second leading cause of cancer death among men in the United States. 1,7-10 However, low test specificity and discrimination have complicated the use and interpretation of PSA as a screening tool.^{9,11} Long-term outcomes data from large population-based randomized PSA screening trials show that it significantly reduces death from prostate cancer but also results in considerable overdiagnosis of low risk disease. 12,13 Screening might be improved were it to account for variation in PSA levels that is attributable to germline genetics rather than PCa. Twin studies and genome-wide association studies (GWAS) have estimated that 30-45% of serum PSA variation is influenced by hereditary factors. 14,15 A recent GWAS meta-analysis from our group identified 128 independent variants associated with serum PSA levels, which explained approximately 9% of genetic variation in PSA. 16,17 Additional genetic variation in PSA levels may be determined by analyses of genes, as opposed to individual variants. Such work could lead to the identification of regions or biological pathways that affect PSA levels and provide clarity on mechanisms underlying constitutional

increases in PSA levels in the absence of carcinogenesis. Transcriptome-wide association studies (TWAS) using expression quantitative trait loci (eQTL) allow for identifying genes whose cisregulated expression is associated with complex polygenic traits. We thus performed a TWAS of PSA levels based on summary statistics from a GWAS meta-analysis of 95,768 men without PCa to identify genes associated with PSA levels and prioritize them for functional investigation. 15,22

Methods

Discovery Populations

A total of 95,768 PCa-free men from the following five study populations were included: UK Biobank, Kaiser Permanente's Genetic Epidemiology Research on Adult Health and Aging, Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Vanderbilt University Medical Center's BioVU, and Malmö Diet and Cancer Study. The men included in these analyses were restricted to PCa-free individuals (i.e., without a PCa diagnosis or history of prostate resection, where information was available). Additionally, analyses were restricted to men with PSA values between 0.01 ng/mL and 10 ng/mL. Additional details about the study cohorts are described in detail in Kachuri et al. and Table S1. Median PSA levels were used for individuals with multiple PSA measurements available, with the exception of PLCO, which used PSA levels at the start of follow-up of the trial.

Quality Control and GWAS Meta-analysis

Genotyping, imputation, study-specific quality control of genetic data, and the GWAS meta-analysis have been previously described for Kachuri et al.¹⁷ Briefly, ancestry and study-specific GWAS analyses used linear regression of log(PSA) on genetic variants, age, and the first 10 genetic ancestry principal components. After results across studies were meta-analyzed within ancestral groups, ancestry-specific summary statistics from individuals of European (n=85,824), African (n=3,509), East Asian (n=3,337), and Hispanic/Latino (n=3,098) ancestry were meta-analyzed to generate multi-ancestry summary statistics.

MetaXcan Transcriptome-wide Gene-based Analysis

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

We undertook a TWAS using the MetaXcan approach, which directly estimates Z-scores for associations between gene expression levels and PSA levels using meta-analyzed GWAS summary statistics with tissue-specific prediction models. Multivariate adaptive shrinkage (mashr) prediction models were trained on GTEx (version 8) eQTL data for whole blood and, separately, prostate tissue. The covariances and weights for models trained on individual tissue types were from the PredictDB Data Repository (https://predictdb.org/). 23 We also undertook a cross-tissue analysis across 45 GTEx tissues that excluded tissues found primarily or exclusively in women to identify potential associations with genes that may have been missed in singletissue analyses. Tissue types found primarily or exclusively in females (mammary breast, ovary, uterus, vagina) were excluded from the multiple tissue analysis. A Bonferroni correction was implemented based on the number of genes tested (whole blood: 0.05/12,192 =4.10e-6; prostate: 0.05/13,844 = 3.61e-6; cross-tissue: 0.05/22,249 = 2.25e-6). Conditional Analysis Ascertaining Independence of TWAS and Previous GWAS Findings To identify the set of TWAS genes for PSA that were novel in comparison to previous GWAS results, we first limited consideration to significant TWAS genes that do not contain genome-wide significant (p < 5e-8) variants from the Kachuri et al GWAS (i.e., within exact gene boundaries). 17 Second, for the remaining genes, we performed conditional analyses using COJO²⁴ that simultaneously modeled eQTLs for a given TWAS-identified gene and GWAS results. For individual tissue analyses, eQTLs used in the prediction models of TWAS-significant genes were selected from the tissue-specific PredictDB TWAS eQTL weight files for each gene. For the cross-tissue analyses, the maximum noncollinear eQTLs (variant inflation factor < 8 within a window size of 50kb) were extracted from all 45 GTEx tissues (i.e., to remove variants

in linkage disequilibrium). COJO was performed using LD reference panels from 10,000 European ancestry UK Biobank participants (as 89.6% of our population was European ancestry). WAS summary statistics were then conditioned on the eQTLs for one gene at a time. If the set of genome-wide significant variants was reduced after conditioning on eQTLs used to predict gene expression, then the eQTLs and GWAS hits were assumed to be in LD and thus not independent of one another. (Methods that assess the conditional fit of eQTLs on GWAS hits are lacking.) However, if the set of genome-wide significant variants remained unchanged after conditional analyses, then we considered the TWAS gene to be independent of GWAS variants from Kachuri et al. 17

Colocalization Analyses

To further investigate whether genes and variants exhibited shared genetic signals, we used fastENLOC software (version 2) to undertake colocalization analyses of eQTLs for all genes with prediction models across TWAS analyses and all variants investigated in the Kachuri et al. GWAS. 17,25,26 For these analyses, LD blocks were based on 1000 Genome Project European ancestry individuals. 27 Z-scores were calculated by dividing the betas from GWAS summary statistics by their standard errors and converting them to posterior inclusion probabilities. 25 Finally, the GWAS summary statistics were colocalized for 49 GTEx version 8 tissues using pre-computed GTEx multiple-tissue annotations. Signal-level results returned regional-level colocalization probabilities (RCP) between eQTL and GWAS signals, which sum up the variant-level colocalization probabilities of correlated variants within an LD block that harbors a single GWAS association signal. Gene-results were based on gene-level regional colocalization probabilities (GRCP), which represent the probability that a candidate gene

contains at least one colocalized variant.²⁶ RCP and GRCP values > 0.5 indicate strong evidence of shared genetic signals between eQTLs and GWAS variants.²⁶

Pathway Enrichment Analysis

To explore the potential biological relevance of PSA-associated genes, we applied the Enrichr tool to all significant genes identified in the whole blood, prostate, and cross-tissue analyses to assess enrichment against three gene set libraries: Kyoto Encyclopedia of Genes and Genomes (KEGG) 2021 human; gene ontology (GO) biological process 2021; and GO molecular function 2021. Enrichment was assessed by multiplying the p-value from a Fisher's exact test with the z-score of the deviation from the expected rank.^{28,29} Pathways with a Benjamini-

Hochberg-corrected p-value < 0.05 were considered significantly enriched.

Results Using MetaXcan and GWAS summary statistics based on 95,769 individuals (Table S1), TWAS analyses were conducted for whole blood, prostate, and cross-tissue matrices. The sample was primarily European (n=85,824), although individuals of African (n=3,509), East Asian (n=3,337), and Hispanic/Latino (n=3,098) ancestry were also included in analyses. The median PSA value across all possible values across different cohorts was 2.35 ng/mL. Whole Blood TWAS In the TWAS based on whole blood gene expression models, 41 out of 12,192 genes were associated with PSA levels at the Bonferroni corrected threshold (Figure 1, Table S2). Expression of 20 genes was positively associated with elevated PSA, and expression of 21 genes was inversely associated. Two of the significant genes are located at 19q13.33, which contains KLK3, the gene encoding serum PSA.³⁰ While a prediction model for KLK3 was not available in whole blood, a member of the same gene family at 19q13.33, KLK2, was the gene most strongly associated with PSA levels (p = 1.28e-62). Twenty-four of the 41 genes did not contain genomewide significant variants and had not been annotated in previous GWAS. Among them, 7 genes were independent of previously published GWAS findings (Table 1). ¹⁷ Of these, increased expression of 6 genes was associated with elevated PSA levels in PCa-free men: GPBP1L1 (1p34.1, p = 2.21e-7); TMEM69 (1p34.1, p = 2.21e-7); UOCRH (1p33, p = 4.76e-7); ACTRT3(3q26.2, p = 5.90e-7); EXOSC9 (4q27, p = 1.80e-6); and CCNA2 (4q27, p = 7.80e-7). Decreased expression of ITH4 was associated with increased PSA levels (3p21.1, p = 3.65e-6).

Prostate Tissue TWAS

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

In TWAS based on prostate tissue gene expression models, 39 out of 13,884 genes were statistically significantly associated with PSA levels (Figure 2, Table S3). Among them, increased expression of 18 and decreased expression of 21 was associated with elevated PSA levels. No prediction models were available for genes in the KLK family in prostate tissue. Instead, MMP7 on 11q22 was most strongly associated with PSA levels (p= 2.78e-18). MMP7 was among 18 PSA-associated TWAS genes containing known genome-wide significant variants. Of the remaining 21 significant genes, six were conditionally independent of previous GWAS results after conditioning on the eQTL variants used in gene prediction models (Table 1). Of these, increased expression of 3 genes was associated with elevated PSA levels: LRRC41 (1p33, p = 4.76e-7), HIST1H2BN (6p22.1, p = 8.86e-8), and HEXIM1 (17q21.31, p = 4.95e-7).Decreased expression of the remaining 3 genes was associated with increased PSA levels: ITIH4 (3p21.1, p = 2.69e-6), EXOSC9 (4q27 p = 1.18e-6), and OTOA (16p12.2, p = 1.44e-6). **Cross-Tissue TWAS** Using S-MultiXcan to integrate signals from 45 tissues excluding tissues primarily or exclusively present in women, we identified 155 out of 22,249 genes whose predicted expression was associated with elevated PSA levels in cross-tissue matrices (Figure 3). Among the 155 statistically significant genes, 8 are located on 19q13.33 and part of the expanded human KLK gene family. We found 71 genes that do not contain genome-wide significant loci within their gene boundaries. Conditional analyses determined that 13 genes from this set were independent of known genome-wide significant variants: CDC42 (1p36.12, p = 6.24e-07), GPBP1L1 (1p34.1, p = 2.08e-08), SLBP (4p16.3, p = 8.40e-08), EXOSC9 (4q27, p = 8.60e-07), CCNA2 (4q27, p = 8.60e-07) 1.02e-06), ANXA8L1 (10q11.22, p = 2.17e-07), RP11-182L21.6 (10q22.3, p = 1.54e-07), E2F7

214 (12q21.2, p = 8.54e-09), C15orf62 (15q15.1, p = 2.01e-07), RP11-327J17.2 (15q26.2, p = 5.82e-09)215 07), C16 or 47 (16q22.3, p = 1.11 e-07), MYOCD (17p12, p = 1.20 E-07), and ABCD4 (17q21.31, p = 1.20 E-07). 216 = 2.17e-06) (Table 1). 217 218 Significant Genes Overlapping Across TWAS 219 Out of the 41 genes that were significantly associated with PSA levels in the whole blood 220 TWAS, 34 were also imputed in the prostate tissue TWAS. Thirty (30) out of 39 significantly 221 associated genes from the prostate tissue TWAS were also evaluated in whole blood analyses. Of 222 the 155 significantly associated genes detected in the cross-tissue analysis, 89 genes and 105 223 genes had transcriptome prediction models available for whole blood and prostate tissues, 224 respectively. 225 Across all TWAS in whole blood, prostate tissue, and cross-tissue models, we identified 226 13 genes whose predicted expression was associated with elevated PSA levels: RAB29 (1q32.1), 227 LDAH (2p24.1), ZFP36L2 (2p21), SIDT1 (3q13.2), TRIM59 (3q25.33), EXOSC9 (4q27), 228 HIBADH (7p15.2), TAX1BP1 (7p15.2), MEGF9 (9q33.2), ADD3 (10q25.1), APIP (11p13), 229 LINC01569 (16p13.3), and EIF2S2 (20q11.22) (Figure 4). Of these genes, only EXOSC9 was 230 conditionally independent after accounting for prior loci and demonstrated evidence of 231 colocalization (described below). Five (5) associations were not statistically significant in the 232 cross-tissue analysis, but had significant tissue-specific signals in whole blood and/or prostate. 233 Seventeen significant genes were shared by only the whole blood and cross-tissue TWAS, six of 234 which did not have prediction models in prostate tissue. Similarly, the prostate tissue and cross-235 tissue TWAS shared 14 significant genes; of these, seven genes did not have prediction models 236 in whole blood.

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

Colocalization Analysis Colocalization identified 372 signals with RCP > 0.5 at the variant level (Table S6) and 307 genes with GRCP > 0.5 at the gene level (Table S7). The top 10 genes with the largest GRCP were OTX1 (2p15), MAFF (22q13.1), FUT2 (19q13.33), EMSY (11q13.5), IFT80 (3q25.33), EXOSC9 (4q27), SMC4 (3q25.33), RCAN3 (1p36.11), PBXIP1 (1q21.3), and PMVK (1q21.3). Of these genes, only EXOSC9 was determined to be independent of previously discovered GWAS loci.¹⁷ Among 155 significant genes from the cross-tissue TWAS, locus-level results identified 50 genes with strong evidence of colocalization (Table 2). Variant-level results identified 66 regions in 51 genes (Table S5). When comparing the overlap between transcriptome-wide significant genes and results from colocalization analyses, we identified 5 novel genes (EXOSC9, CCNA2, HIST1H2BN, RP11-182L21.6, and RP11-327J17.2) with GRCP/RCP > 0.5. Two of these genes are long non-coding RNA while the remaining three are protein-coding genes. Pathway Enrichment Analysis TWAS genes were significantly enriched in 23 pathways underlying molecular activities and biological processes present in KEGG and GO gene set databases (Table 3, Figure 5). Enrichment analyses in the whole blood gene set identified the renin-angiotensin-aldosterone system in KEGG, which works to regulate arterial blood pressure. No pathways were significantly enriched by prostate and cross-tissue gene sets in the KEGG catalog. Enrichment analyses within the GO biological process and molecular function gene set libraries identified 23 pathways that were significantly enriched in the cross-tissue gene set. No

pathways were significantly enriched in GO for whole blood nor prostate tissue TWAS sets. Of note, the biological process underlying the regulation of cyclin-dependent protein serine/threonine kinase (CDK) activity in cell cycle progression is particularly relevant for the function of *CCNA2*. We also observed enrichment in 13 pathways involving both single and double stranded DNA binding mechanisms and regulation by transcription factors, including RNA polymerase II (pol II), a core component of the DNA transcription machinery. Moreover, two pathways underlying extracellular matrix and cellular component disassembly were enriched in the cross-tissue gene set. Analogous to the findings in KEGG for the whole blood TWAS, biological pathways underlying the regulation of systemic arterial blood pressure were also identified in the GO biological process catalog.

Discussion

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

This TWAS of 95,768 PCa-free men identified 173 genes whose predicted expression levels were significantly associated with PSA. Conditional analyses identified 20 novel candidate susceptibility genes for PSA, and colocalization analyses highlighted five of them: EXOSC9 and CCNA2 at 4q27, HIST1H2BN at 6p22.1, RP11-182L21.6 at 10q22.3, and RP11-327J17.2 at 15q26.2. Pathway enrichment analyses across three gene ontology catalogs implicated regulatory pathways related to transcription, cell signaling, and disassembly of cellular and noncellular components such as the extracellular matrix. The five colocalized genes introduce new hypotheses and insights regarding the genetic mechanisms regulating PSA production. Of particular interest are the signals at the 4q27 locus (EXOSC9 and CCNA2), a genomic region that was not detected in previous GWAS of PSA. 16,17 Researchers have previously investigated an autoimmune related block on the 4q27 locus and did not find an association with PCa risk. 32-35 EXOSC9, which encodes a core protein involved in the RNA degradation machinery in humans, was identified across all three TWAS analyses. Currently, there is no literature supporting an association between EXCOSC9 and PSA levels or PCa risk. Genetically predicted expression of EXOSC9 in whole blood was positively associated with PSA levels, while the opposite direction of effect was observed for expression in prostate tissue. There exists limited tissue-specific knowledge of the physiological and pathological function of EXOSC9 in non-cancer cell lines. 34,35 Literature documenting the relationship between CCNA2 and PSA is also limited, though CCNA2 was previously tested as a candidate autoantibody signature marker for distinguishing PCa from BPH in patients with elevated serum PSA:36 it was not determined to be a top antibody signature of any specific PCa targets. Gene coexpression network analyses have linked CCNA2 to biochemical recurrence and survival in men

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

with PCa. ^{37,38} Further exploration of *CCNA2* expression in individuals without PCa may unveil biological pathways that influence PSA levels. Pathway enrichment results also highlighted a number of interesting pathways involving Pol II, which plays a critical role in the regulated synthesis of both protein-coding and noncoding messenger RNA in eukaryotic genomes. 39-41 In addition to its numerous roles in DNA transcription, Pol II is known to associate with androgen receptor binding regions of the PSA enhancer and promoter to initiate androgen-dependent transcription. 42 The two colocalized lncRNA genes, RP11-182L21.6 and RP11-327J17.2, could feasibly regulate epigenetic modification through histone or DNA acetylation or methylation. ⁴³ That histone deacetylase binding was enriched in our pathway analyses suggests a possible mechanism through which lncRNAs could affect constitutive PSA levels. Aberrant expression of various lncRNA products has also been observed for various cancers, including PCa.⁴⁴ Because PSA is used for both PCa detection and monitoring of PCa progression, it is difficult to disentangle the mechanisms underlying our observed associations. PSA-related screening bias may account for a portion of the observed relationship between gene expression and PSA levels. Genes may also exert pleiotropic effects on PCa and PSA through overlapping biological mechanisms.^{1,9} Nevertheless, our restriction to PCa-free men for all analyses minimizes the potential for reverse causation and bolsters confidence that the observed genetic signals inform constitutive PSA levels. Fourteen of the 20 novel PSA-related genes identified from conditional analyses, spanning 12 genomic regions not implicated by prior PSA GWAS, have been associated with prostatic malignancies: CDC42 (1p36.12), GPBP1L1 and TMEM69 (1p34.1), LRRC41 (1p33), ITIH4 (3p21.1), SLBP (4p16.3), CCNA2 (4q27), HIST1H2BN (6p22.1), ANXA8L1 (10q11.2), E2F7 (12q21.2), C15orf62 (15q15.1), OTOA (16p12.2),

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

C16orf47 (16q22.3), and HEXIM1(17q21.31). 45-55 Colocalized gene HIST1H2BN, which encodes a component of a core nucleosome histone, has been linked to PCa cell growth and epithelial-mesenchymal transition through upregulated NF-kB/Rel expression. 45 Activation of the NF-kB pathway can induce activation of the PSA promoter-enhancer, even in the absence of androgens, and NF-kB can directly bind to the PSA enhancer in prostate cancer cell lines. ⁵⁶ To our knowledge, no experiments have been conducted to investigate the relationship between NFkB and PSA in PCa-free populations. Conditional analyses further identified 6 genes that have not been implicated in PCa susceptibility in gene function, experimental, or human population research: *UOCRH* (1p33), ACTRT3 (3q26.2), EXOSC9 (4q27), RP11-182L21.6 (10q22.3), RP11-327J17.2 (15q26.2), and ACBD4 (17q21.31). ACTRT3 is of particular interest, as it is critical in regulating sperm nucleus cytomorphology upstream of the processing of spermatid into mature motile sperm. ⁵⁷ Increased expression of ACTRT3, which forms a testis-specific profilin III-ACTRT3 complex that facilitates male germ cell head cytomorphology and maintains sperm motility in animal models, was associated with elevated PSA levels in the TWAS based on whole blood. 57,58 Though there is no documented link between ACTRT3 and PSA levels or PCa risk, the pronounced role of ACTRT3 in mediating conformational changes in sperm nuclei suggests possible shared biological pathways between PSA and the production and processing of male germ cells.^{5,57} Loci that map to the multigenic region that contains ACTRT3 have been linked to melanoma, colorectal cancer. and lung cancer susceptibility. ^{59–61} The functional role of *ACTRT3* is poorly characterized and warrants further analysis. Our study had several limitations. First, nearly 90% of men in the study population were of primarily European ancestry, and 85% of the tissue samples used to train the TWAS models

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

were derived from European populations. 62 Therefore, our TWAS may have missed ancestryspecific signals, and our findings may not be generalizable to broader ancestral populations. To better characterize the genetic mechanisms underlying circulating PSA levels, it will be imperative for future analyses to expand to multi-ethnic populations; diversity in genetic studies of PSA levels is critical for equitably improving PSA screening. 63 Second, our study assessed only cis-eQTLs, so any trans-eQTL effects are not incorporated. Third, colocalization analyses have a high type 2 error rate and may be underpowered to detect shared association signals.²⁶ Fourth, although we restricted our analyses to men who had not been diagnosed with PCa, we cannot rule out the possibility of latent, undiagnosed disease or disease diagnosed at a later timepoint. However, the prevalence of undiagnosed PCa in our population was likely to be low on account of low prevalence at the time of the first PSA measurement or increased monitoring and surveillance in longitudinal cohorts. ^{7,9} Finally, many of the novel genes that we identified were clustered at multi-gene loci, in part due to co-regulation by a shared set of eQTLs. Sentinel genes at these loci should be interpreted with caution, as there may be correlated predicted expression.⁶⁴ Our study also had several key strengths. The use of GWAS summary statistics from a cohort of 95,768 men provided us with high statistical power to quantify PSA-associated genes. In addition to conducting tissue-specific association analyses in tissues that are biologically meaningful for PSA, we integrated association signals across 45 GTEx tissues to improve power for genes with similar regulatory mechanisms across tissues. This method allowed us to capture PSA-related genes with expression patterns that were significant for specific tissues, as well as genes with expression that was similar across multiple tissues. Our study also used COJO analysis to find novel genes conditionally independent from known GWAS variants.

In summary, our TWAS identified gene expression profiles associated with PSA levels in men without PCa. These findings provide several novel hypotheses for genes that affect constitutive PSA. Further exploration of these results, including functional analyses of these genes in in-vivo settings, will augment our understanding of the genetic etiology of PSA variation. Transcriptomic analyses might also be vertically integrated with downstream -omic approaches to uncover complete mechanisms through which genetics influence circulating PSA levels. In addition, TWAS findings may be used to develop polygenic transcriptome risk scores⁶⁵ for PSA levels, which could be leveraged for improving PSA as a tool for PCa screening.

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

Declaration of Interests: JSW is a non-employee, cofounder of Avail Bio. HL is named on a patent for assays to measure intact prostate-specific antigen and a patent for a statistical method to detect prostate cancer commercialized by OPKO Health (4KScore). HL receives royalties from sales of the assay and has stock in OPKO Health. HL serves on the Scientific Advisory Board for Fujirebio Diagnostics Inc and owns stock in Diaprost AB and Acousort AB. **Data Availability:** GWAS summary statistics used in this analysis are available for download from Kachuri et al are available from the following Zenodo repository: https://doi.org/10.5281/zenodo.7460134. Transcriptome prediction weights and models used for MetaXcan analyses are available from: https://predictdb.org. **Funding sources:** The Precision PSA study is supported by funding from the National Institutes of Health (NIH) and National Cancer Institute (NCI) under award number R01CA241410 (PI: JSW). REG is supported by a Prostate Cancer Foundation Young Investigator Award. LK is supported by funding from National Cancer Institute (R00CA246076). JPS is supported by funding from the National Institute of General Medical Sciences (T32GM007347). HL is supported in part by funding from NIH/NCI (P30-CA008748, U01-CA199338, R01CA244948) and the Swedish Cancer Society (Cancerfonden 20 1354 PjF). RK is supported by funding from the NIH (R01 CA244948 and R01 CA175491). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

References Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268-278. doi:10.1038/nrc2351 2. Cucchiara V, Cooperberg MR, Dall'Era M, et al. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018;73(4):572-582. doi:10.1016/j.eururo.2017.10.036 3. LeBeau AM, Kostova M, Craik CS, Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biol Chem. 2010;391(4):333-343. doi:10.1515/BC.2010.044 4. Qiu SD, Young CY, Bilhartz DL, et al. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol. 1990;144(6):1550-1556. doi:10.1016/s0022-5347(17)39797-5 Lilia H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their 5. reactions during gelation and liquefaction of human semen. J Clin Invest. 1987;80(2):281-285. Pinsky PF, Kramer BS, Crawford ED, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. *Urology*. 2006;68(2):352-356. doi:10.1016/j.urology.2006.02.026 7. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer.

Cochrane Database Syst Rev. 2013;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.

411 8. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-412 Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US 413 Preventive Services Task Force. *JAMA*. 2018;319(18):1914-1931. 414 doi:10.1001/jama.2018.3712 415 9. Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific 416 antigen (PSA) test: a systematic review and meta-analysis. The BMJ. 2018;362:k3519. 417 doi:10.1136/bmj.k3519 418 10. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of 419 prostate cancer in the United States. Epidemiol Rev. 2001;23(1):181-186. 420 doi:10.1093/oxfordjournals.epirev.a000787 421 11. Han PKJ, Kobrin S, Breen N, et al. National Evidence on the Use of Shared Decision 422 Making in Prostate-Specific Antigen Screening. Ann Fam Med. 2013;11(4):306-314. 423 doi:10.1370/afm.1539 424 12. Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr Follow-up of the European 425 Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43-51. 426 doi:10.1016/j.eururo.2019.02.009 427 13. de Koning HJ, Gulati R, Moss SM, et al. The efficacy of prostate-specific antigen 428 screening: Impact of key components in the ERSPC and PLCO trials. Cancer.

2018;124(6):1197-1206. doi:10.1002/cncr.31178

429

- 430 14. Bansal A, Murray DK, Wu JT, Stephenson RA, Middleton RG, Meikle AW. Heritability of
- Prostate-Specific Antigen and Relationship with Zonal Prostate Volumes in Aging Twins*.
- 432 *J Clin Endocrinol Metab.* 2000;85(3):1272-1276. doi:10.1210/jcem.85.3.6399
- 433 15. Pilia G, Chen WM, Scuteri A, et al. Heritability of Cardiovascular and Personality Traits in
- 434 6,148 Sardinians. *PLoS Genet*. 2006;2(8):e132. doi:10.1371/journal.pgen.0020132
- 435 16. Hoffmann TJ, Passarelli MN, Graff RE, et al. Genome-wide association study of prostate-
- specific antigen levels identifies novel loci independent of prostate cancer. *Nat Commun*.
- 437 2017;8:14248. doi:10.1038/ncomms14248
- 438 17. Kachuri L, Hoffmann TJ, Jiang Y, et al. Incorporating Genetic Determinants of Prostate-
- Specific Antigen Levels Improves Prostate Cancer Screening. *MedRvix*.
- 440 doi:10.1101/2022.04.18.22273850
- 18. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are
- more likely to be eQTLs: annotation to enhance discovery from GWAS. *PLoS Genet*.
- 443 2010;6(4):e1000888. doi:10.1371/journal.pgen.1000888
- 444 19. Gamazon ER, Wheeler HE, Shah KP, et al. A gene-based association method for mapping
- traits using reference transcriptome data. *Nat Genet*. 2015;47(9):1091-1098.
- 446 doi:10.1038/ng.3367
- 447 20. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide
- 448 association studies. *Nat Genet*. 2016;48(3):245-252. doi:10.1038/ng.3506

449 21. Pasaniuc B, Price AL. Dissecting the genetics of complex traits using summary association 450 statistics. Nat Rev Genet. 2017;18(2):117-127. doi:10.1038/nrg.2016.142 451 22. Barbeira AN, Dickinson SP, Bonazzola R, et al. Exploring the phenotypic consequences of 452 tissue specific gene expression variation inferred from GWAS summary statistics. *Nat* 453 Commun. 2018;9(1):1825. doi:10.1038/s41467-018-03621-1 454 23. Barbeira, A.N., Bonazzola, R., Gamazon, E.R. □ et al. □ Exploiting the GTEx resources to 455 decipher the mechanisms at GWAS loci. ☐ Genome Biol. 2021;22(49). doi: 10.1186/s13059-456 020-02252-4 457 Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 458 459 2012;44(4):369-S3. doi:10.1038/ng.2213 460 25. Wen X, Pique-Regi R, Luca F. Integrating molecular QTL data into genome-wide genetic 461 association analysis: Probabilistic assessment of enrichment and colocalization. PLOS 462 Genet. 2017;13(3):e1006646. doi:10.1371/journal.pgen.1006646 463 26. Hukku A, Sampson MG, Luca F, Pique-Regi R, Wen X. Analyzing and reconciling 464 colocalization and transcriptome-wide association studies from the perspective of 465 inferential reproducibility. Am J Hum Genet. 2022;109(5):825-837. 466 doi:10.1016/j.ajhg.2022.04.005 467 27. Berisa T, Pickrell JK. Approximately independent linkage disequilibrium blocks in human 468 populations. Bioinformatics. 2016;32(2):283-285. doi:10.1093/bioinformatics/btv546

- 28. Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list
- 470 enrichment analysis tool. *BMC Bioinformatics*. 2013;14(1):128. doi:10.1186/1471-2105-14-
- 471 128
- 472 29. Xie Z, Bailey A, Kuleshov MV, et al. Gene Set Knowledge Discovery with Enrichr. Curr
- 473 *Protoc.* 2021;1(3):e90. doi:10.1002/cpz1.90
- 474 30. Balk SP, Ko YJ, Bubley GJ. Biology of Prostate-Specific Antigen. *J Clin Oncol*.
- 475 2003;21(2):383-391. doi:10.1200/JCO.2003.02.083
- 476 31. Barbeira AN, Pividori M, Zheng J, Wheeler HE, Nicolae DL, Im HK. Integrating predicted
- 477 transcriptome from multiple tissues improves association detection. *PLOS Genet*.
- 478 2019;15(1):e1007889. doi:10.1371/journal.pgen.1007889
- 479 32. Tindall EA, Hoang HN, Southey MC, et al. The 4g27 locus and prostate cancer risk. *BMC*
- 480 *Cancer*. 2010;10(1):69. doi:10.1186/1471-2407-10-69
- 481 33. Yoshino S, Hara T, Weng JS, Takahashi Y, Seiki M, Sakamoto T. Genetic Screening of
- New Genes Responsible for Cellular Adaptation to Hypoxia Using a Genome-Wide shRNA
- 483 Library. *PLoS ONE*. 2012;7(4):e35590. doi:10.1371/journal.pone.0035590
- 484 34. Yoshino S, Matsui Y, Fukui Y, et al. EXOSC9 depletion attenuates P-body formation,
- stress resistance, and tumorigenicity of cancer cells. *Sci Rep.* 2020;10(1):9275.
- 486 doi:10.1038/s41598-020-66455-2

487 35. Burns DT, Donkervoort S, Müller JS, et al. Variants in EXOSC9 Disrupt the RNA 488 Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy. Am J Hum 489 Genet. 2018;102(5):858-873. doi:10.1016/j.ajhg.2018.03.011 490 36. O'Rourke DJ, DiJohnson DA, Caiazzo RJ, et al. Autoantibody Signatures as Biomarkers to 491 Distinguish Prostate Cancer from Benign Prostatic Hyperplasia in Patients with Increased 492 Serum Prostate Specific Antigen. Clin Chim Acta Int J Clin Chem. 2012;413(5-6):561-567. 493 doi:10.1016/j.cca.2011.11.027 494 37. Feng T, Wei D, Li Q, et al. Four Novel Prognostic Genes Related to Prostate Cancer 495 Identified Using Co-expression Structure Network Analysis. Front Genet. 2021;12. doi: 10.3389/fgene.2021.584164 496 497 38. Yang R, Du Y, Wang L, Chen Z, Liu X. Weighted gene co-expression network analysis 498 identifies CCNA2 as a treatment target of prostate cancer through inhibiting cell cycle. J 499 Cancer. 2020;11(5):1203-1211. doi:10.7150/jca.38173 500 Smale ST, Kadonaga JT. The RNA polymerase II core promoter. Annu Rev Biochem. 501 2003;72:449-479. doi:10.1146/annurev.biochem.72.121801.161520 502 40. Wagner SD, Yakovchuk P, Gilman B, et al. RNA polymerase II acts as an RNA-dependent 503 RNA polymerase to extend and destabilize a non-coding RNA. EMBO J. 2013;32(6):781-504 790. doi:10.1038/emboj.2013.18 505 Schier AC, Taatjes DJ. Structure and mechanism of the RNA polymerase II transcription 506 machinery. Genes Dev. 2020;34(7-8):465-488. doi:10.1101/gad.335679.119

507	42.	Louie MC, Yang HQ, Ma AH, et al. Androgen-induced recruitment of RNA polymerase II
508		to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci. 2003;100(5):2226-
509		2230. doi:10.1073/pnas.0437824100
510	12	Thong V. Wong W. Thu W. et al. Machanisms and Eurotions of Long Non-Coding DNAs
510	43.	Zhang X, Wang W, Zhu W, et al. Mechanisms and Functions of Long Non-Coding RNAs
511		at Multiple Regulatory Levels. <i>Int J Mol Sci.</i> 2019;20(22):5573. doi:10.3390/ijms20225573
512	44.	Misawa A, Takayama K, Inoue S. Long non-coding RNAs and prostate cancer. <i>Cancer Sci.</i>
513		2017;108(11):2107-2114. doi:10.1111/cas.13352
514	45.	Zhang, J., Chang, Y., Xia, H. □ et al. □ HIST1H2BN induced cell proliferation and EMT
515		phenotype in prostate cancer via NF-κB signal pathway. ☐ Genes Genom. 2021;43:1361-
516		1369. doi: 10.1007/s13258-021-01164-2
517	46.	Liu Q, Reed M, Zhu H, et al. Epigenome-wide DNA methylation and transcriptome
518		profiling of localized and locally advanced prostate cancer: Uncovering new molecular
519		markers. Genomics. 2022;114(5):110474. doi:10.1016/j.ygeno.2022.110474
520	47.	Pressinotti NC, Klocker H, Schäfer G, et al. Differential expression of apoptotic genes
521		PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol
522		Cancer. 2009;8:130. doi:10.1186/1476-4598-8-130
523	48.	Mahajan NP, Liu Y, Majumder S, et al. Activated Cdc42-associated kinase Ack1 promotes
524		prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad
525		Sci U S A. 2007;104(20):8438-8443. doi:10.1073/pnas.0700420104

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

49. Davalieva K, Kiprijanovska S, Komina S, Petrusevska G, Zografska NC, Polenakovic M. Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. Proteome Sci. 2015;13:2. doi:10.1186/s12953-014-0059-9 50. Krishnan N, Titus MA, Thapar R. The Prolyl Isomerase Pin1 Regulates mRNA Levels of Genes with Short Half-Lives by Targeting Specific RNA Binding Proteins. *PLOS ONE*. 2014;9(1):e85427. doi:10.1371/journal.pone.0085427 51. Wang Y, Pei X, Xu P, et al. E2F7, regulated by miR 230c, inhibits apoptosis and promotes cell cycle of prostate cancer cells. Oncol Rep. 2020;44(3):849-862. doi:10.3892/or.2020.7659 Sheeba JDJ, Hegde S, Tamboli N, Nadig N, Keshavamurthy R, Ranganathan P. Gene expression signature of castrate resistant prostate cancer. *BioRxiv*. 2022.03.16.484397. doi:10.1101/2022.03.16.484397 Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castrationresistant prostate cancer. *Nature*. 2012;487(7406):239-243. doi:10.1038/nature11125 54. Lew QJ, Chu KL, Chia YL, Cheong N, Chao SH. HEXIM1, a New Player in the p53 Pathway. Cancers. 2013;5(3):838-856. doi:10.3390/cancers5030838 55. Chen R, Yik JHN, Lew QJ, Chao SH. Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer. BioMed Res Int. 2014;2014:e232870. doi:10.1155/2014/232870

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

56. Chen CD, Sawyers CL. NF-κB Activates Prostate-Specific Antigen Expression and Is Upregulated in Androgen-Independent Prostate Cancer. Mol Cell Biol. 2002;22(8):2862-2870. doi:10.1128/MCB.22.8.2862-2870.2002 57. Hara Y, Yamagata K, Oguchi K, Baba T. Nuclear localization of profilin III-ArpM1 complex in mouse spermiogenesis. FEBS Lett. 2008;582(20):2998-3004. doi:10.1016/j.febslet.2008.07.058 58. Umer N, Arévalo L, Phadke S, et al. Loss of Profilin3 Impairs Spermiogenesis by Affecting Acrosome Biogenesis, Autophagy, Manchette Development and Mitochondrial Organization. Front Cell Dev Biol. 2021;9 9:749559. doi: 10.3389/fcell.2021.749559 59. Song F, Amos CI, Lee JE, et al. Identification of a melanoma susceptibility locus and somatic mutation in TET2. Carcinogenesis. 2014;35(9):2097-2101. doi:10.1093/carcin/bgu140 60. Law PJ, Timofeeva M, Fernandez-Rozadilla C, et al. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat Commun. 2019;10(1):2154. doi:10.1038/s41467-019-09775-w 61. McKay JD, Hung RJ, Han Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017;49(7):1126-1132. doi:10.1038/ng.3892 62. THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318-1330. doi:10.1126/science.aaz1776

564 63. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current 565 polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591. 566 doi:10.1038/s41588-019-0379-x 567 64. Wainberg M, Sinnott-Armstrong N, Mancuso N, et al. Opportunities and challenges for 568 transcriptome-wide association studies. Nat Genet. 2019;51(4):592-599. 569 doi:10.1038/s41588-019-0385-z 570 65. Liang, Y., Pividori, M., Manichaikul, A. □ et al. □ Polygenic transcriptome risk scores 571 (PTRS) can improve portability of polygenic risk scores across ancestries. □ *Genome* 572 *Biol* □ 2022;23(23). doi: 10.1186/s13059-021-02591-w

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

Figure Titles and Legends: Figures 1-3. TWAS results by chromosome, as depicted by (1) Miami plot for whole blood analyses, (2) Miami plot for prostate tissue analyses, and (3) Manhattan plot for cross-tissue analyses. Each dot represents a gene, and the red dashed lines represent the significance thresholds after Bonferroni correction (whole blood: 4.10e-6, prostate: 3.61e-6, cross-tissue: 2.25e-6). For the Miami plots in figures 1 and 2, all statistically significant genes are annotated, and the genes independent of results from the largest prior GWAS are highlighted in yellow; the genes in the upper half of the plots were positively associated with PSA levels, and the genes in the lower half of the plots were inversely associated with PSA levels. For the Manhattan plot in figure 3, the 30 genes with the smallest association p-values are annotated and colored blue, and significant genes from the whole blood and prostate tissue analyses are annotated and colored vellow. Directions of association between genes and PSA levels are not available for cross-tissue analyses due to the joint tissue inference methodology used in S-MultiXcan. Figure 4. Statistically significant genes overlapping across TWAS analyses. Of the significant gene sets from whole blood (41 genes), prostate tissue (39 genes), and cross-tissue analyses (155 genes), 13 genes were significant across all three analyses, 36 genes were significant in exactly two analyses, and 124 genes were significant in a single analysis. Figure 5. GO term enrichment results from the cross-tissue TWAS. The GO molecular function and biological process data repositories were queried for pathway enrichment analyses. The color gradient represents the magnitude of p-values, with darker colors corresponding to smaller values. The size of the circles represents the number of genes in the pathway.

Table Titles

594

595

596

Table 1. Novel genes associated with prostate-specific antigen (PSA) levels in transcriptome-

wide association studies (TWAS) based on whole blood, prostate, and cross-tissue predicted

597 gene expression*

Ensembl gene ID	Gene name	Chr	Cytoband†	Analysis~	Z- score	Beta	p	p-bonf
ENSG00000132128	LRRC41	1	p33	Prostate	5.04	0.29	4.76E-07	6.59E-03
				Whole Blood	5.18	17.92	2.21E-07	2.69E-03
ENSG00000159592	GPBP1L1	1	p34.1	Cross-Tissue	-1.92	-	2.08E-08	4.59E-04
ENSG00000159596	TMEM69	1	p34.1	Whole Blood	5.18	0.28	2.21E-07	2.69E-03
ENSG00000173660	UQCRH	1	p33	Whole Blood	5.04	8.04	4.76E-07	5.80E-03
ENSG00000070831	CDC42	1	p36.12	Cross-Tissue	-1.55	-	6.24E-07	1.37E-02
ENSG00000184378	ACTRT3	3	q26.2	Whole Blood	4.99	0.25	5.90E-07	7.19E-03
				Whole Blood	-4.63	-0.03	3.65E-06	4.45E-02
ENSG00000055955	ITIH4	3	p21.1	Prostate	-4.69	-0.03	2.69E-06	3.72E-02
ENSG00000163950	SLBP	4	p16.3	Cross-Tissue	-2.15	-	8.40E-08	1.85E-03
				Whole Blood	4.94	0.61	7.80E-07	9.51E-03
ENSG00000145386	CCNA2	4	q27	Cross-Tissue	-1.81	-	1.02E-06	2.25E-02
				Whole Blood	4.77	0.09	1.80E-06	2.19E-02
				Prostate	-4.86	-0.42	1.18E-06	1.63E-02
ENSG00000123737	EXOSC9	4	q27	Cross-Tissue	0.36	-	8.60E-07	1.89E-02
ENSG00000233822	HIST1H2BN	6	p22.1	Prostate	5.35	0.24	8.86E-08	1.23E-03
	RP11-							
ENSG00000272447	182L21.6	10	q22.3	Cross-Tissue	1.25	-	1.54E-07	3.40E-03
ENSG00000264230	ANXA8L1	10	q11.22	Cross-Tissue	-0.46	-	2.17E-07	4.77E-03
ENSG00000165891	E2F7	12	q21.2	Cross-Tissue	1.45	-	8.54E-09	1.88E-04
ENSG00000188277	C15orf62	15	q15.1	Cross-Tissue	-0.85	-	2.01E-07	4.42E-03
	RP11-							
ENSG00000259359	<i>327J17.2</i>	15	q26.2	Cross-Tissue	-0.16	-	5.82E-07	1.28E-02
ENSG00000155719	OTOA	16	p12.2	Prostate	-4.82	-5.36	1.44E-06	1.99E-02
ENSG00000197445	C16orf47	16	q22.3	Cross-Tissue	0.44	-	1.11E-07	2.47E-03
ENSG00000141052	MYOCD	17	p12	Cross-Tissue	-3.03	-	1.20E-07	2.66E-03
ENSG00000181513	ACBD4	17	q21.31	Cross-Tissue	-1.05	-	2.17E-06	4.77E-02
ENSG00000186834	HEXIM1	17	q21.31	Prostate	5.03	0.12	4.95E-07	6.85E-03

Abbreviations: Chr – chromosome; p-bonf – Bonferroni-adjusted p-value

^{*} The genes included in this table were significant (Bonferroni-adjusted p < 0.05) in at least one TWAS and, based on conditional analyses, independent from the largest prior genome-wide association study of PSA levels. † GRCh38

[~] Indicates the tissue(s) in which predicted gene expression was significantly associated with PSA levels.

Table 2. Gene level colocalization results for significant genes from the cross-tissue

transcriptome-wide association study*

598

599

Ensembl gene ID	Gene name	Chr	Cytoband†	GRCP	GLCP
ENSG00000069275	NUCKS1	1	q32.1	0.97	2.55
ENSG00000117280	RAB29	1	q32.1	1.13	0.52
ENSG00000117602	RCAN3	1	p36.11	2.13	-24.54
ENSG00000143603	KCNN3	1	q21.3	1.42	-136.50
ENSG00000158715	SLC45A3	1	q32.1	0.59	15.17
ENSG00000163344	PMVK	1	q21.3	1.97	-50.77
ENSG00000163346	PBXIP1	1	q21.3	1.99	-14.21
ENSG00000270361	RP11-307C12.13	1	q21.3	1.08	-0.32
ENSG00000115507	OTX1	2	p15	4.91	-7.33
ENSG00000143869	GDF7	2	p24.1	1.00	620.30
ENSG00000068885	IFT80	3	q25.33	2.41	24.05
ENSG00000072858	SIDT1	3	q13.2	0.62	-211.30
ENSG00000113810	SMC4	3	q25.33	2.18	-52.64
ENSG00000132394	EEFSEC	3	q21.3	1.34	-160.40
ENSG00000175792	RUVBL1	3	q21.3	1.24	-72.12
ENSG00000177311	ZBTB38	3	q23	1.22	-39.66
ENSG00000186432	KPNA4	3	q25.33	1.27	-19.18
ENSG00000213186	TRIM59	3	q25.33	1.54	-38.26
ENSG00000123737	EXOSC9	4	q27	2.24	-108.20
ENSG00000145386	CCNA2	4	q27	1.39	-54.29
ENSG00000049656	CLPTM1L	5	p15.33	0.71	-27.67
ENSG00000164362	TERT	5	p15.33	0.72	4.54
ENSG00000184357	HIST1H1B	6	p22.1	0.92	2.70
ENSG00000189298	ZKSCAN3	6	p22.1	0.84	1.28
ENSG00000204713	TRIM27	6	p22.1	0.76	-12.84
ENSG00000233822	HIST1H2BN	6	p22.1	1.08	-9.88
ENSG00000281831	HCP5B	6	p22.1	0.88	1.25
ENSG00000164684	ZNF704	8	q21.13	1.00	-94.45
ENSG00000167034	NKX3-1	8	p21.2	0.96	-293.10
ENSG00000056558	TRAF1	9	q33.2	0.78	5,137.00
ENSG00000095261	PSMD5	9	q33.2	0.61	-14.25
ENSG00000119403	PHF19	9	q33.2	0.97	-23.73
ENSG00000130956	HABP4	9	q22.32	0.82	30.20
ENSG00000130958	SLC35D2	9	q22.32	1.22	-11.44
ENSG00000165244	ZNF367	9	q22.32	0.60	-10.13
ENSG00000148700	ADD3	10	q25.1	1.21	-118.60
ENSG00000272447	RP11-182L21.6	10	q22.3	0.99	5.94
ENSG00000137673	MMP7	11	q22.2	0.96	183.70
ENSG00000158636	EMSY	11	q13.5	2.64	-9.56
ENSG00000177951	BET1L	11	p15.5	0.78	-63.92
ENSG00000111707	SUDS3	12	q24.23	1.33	-225.60
ENSG00000175899	A2M	12	p13.31	0.64	-156.60
ENSG00000172766	NAA16	13	q14.11	1.25	-14.31
ENSG00000259359	RP11-327J17.2	15	q26.2	1.10	2.93

ENSG00000141052	MYOCD	17	p12	0.62	-1.94
ENSG00000275410	HNF1B	17	q12	0.81	2.32
ENSG00000176920	FUT2	19	q13.33	3.04	320.20
ENSG00000177045	SIX5	19	q13.32	1.87	-15.39
ENSG00000185800	DMWD	19	q13.32	1.00	461.40
ENSG00000185022	MAFF	22	q13.1	3.63	3.06

Abbreviations: Chr – chromosome; GLCP - gene-level colocalization probability; GRCP - gene-level variant colocalization probability

^{*} The genes in bold were, based on COJO analyses, independent from the largest prior genome-wide association study of prostate-specific antigen levels.

[†] GRCh38

Table 3. Results from pathway analyses based on all significant genes identified in the whole blood,

prostate tissue, and cross-tissue transcriptome-wide association studies

600

601

Database	Pathway	Overlap	p	Score	Genes
	+		hole Blood	1	
KEGG	renin-angiotensin system	2/23	0.047	335.87	KLK1;KLK2
	T	Cı	ross-Tissue		EHE ZDZD4 EZGO CLIGO HOVATO DOUS
GO Molecular Function	RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977)	26/1359	6.82E-04	30.85	EHF;ZBTB4;ETS2;GLIS2;HOXA10;POU5 F1B;PGBD1;HOXA9;SIX5;ZNF704;ZKSC AN3;OTX1;ZBTB7B;ZNF367;E2F7;NKX3- 1;NKX2- 6;BCL11A;ZBTB38;HNF1B;TBX3;DMRTA 2;TFAP4;MAFF;MKX;TP53
GO Molecular Function	sequence-specific double- stranded DNA binding (GO:1990837)	14/712	0.024	18.07	ETS2;TBX3;GLIS2;HOXA10;DMRTA2;HO XA9;TFAP4;ZNF704;MAFF;OTX1;ZBTB7 B;TP53;E2F7;NKX3-1
GO Molecular Function	double-stranded DNA binding (GO:0003690)	14/651	0.013	22.45	NUCKS1;ETS2;TBX3;GLIS2;HOXA10;DM RTA2;HOXA9;TFAP4;ZNF704;MAFF;OT X1;ZBTB7B;E2F7;NKX3-1
GO Molecular Function	RNA polymerase II cisregulatory region sequence- specific DNA binding (GO:0000978)	26/1149	6.54E-05	47.24	EHF;ZBTB4;ETS2;GLIS2;HOXA10;POU5 F1B;PGBD1;HOXA9;SIX5;ZNF704;ZKSC AN3;OTX1;ZBTB7B;ZNF367;E2F7;NKX3- 1;NKX2- 6;BCL11A;ZBTB38;HNF1B;TBX3;DMRTA 2;TFAP4;MAFF;MKX;TP53
GO Molecular Function	cis-regulatory region sequence-specific DNA binding (GO:0000987)	27/1149	3.69E-05	53.95	EHF;ZBTB4;ETS2;GLIS2;HOXA10;POU5 F1B;PGBD1;HOXA9;SIX5;ZNF704;ZKSC AN3;OTX1;ZBTB7B;ZNF367;E2F7;NKX3- 1;NKX2- 6;BCL11A;ZBTB38;HMGA1;HNF1B;TBX3 ;DMRTA2;TFAP4;MAFF;MKX;TP53
GO Molecular Function	sequence-specific DNA binding (GO:0043565)	17/707	0.0012	35.01	ZBTB38;ZBTB4;ETS2;TBX3;GLIS2;HOXA 10;DMRTA2;HOXA9;TFAP4;TERT;ZNF70 4;MAFF;ZKSCAN3;OTX1;ZBTB7B;E2F7; NKX3-1
GO Molecular Function	endopeptidase activity (GO:0004175)	8/315	0.049	19.86	MMP7;KLK1;ADAMTS18;KLK5;KLK3;KL K15;KLK2;KLK8
GO Molecular Function	histone deacetylase binding (GO:0042826)	5/1993	0.016	53.49	HOXA10;TFAP4;SUDS3;TP53;NKX3-1
GO Molecular Function	serine-type endopeptidase activity (GO:0004252)	6/105	0.0047	69.79	KLK1;KLK5;KLK3;KLK15;KLK2;KLK8
GO Molecular Function	serine-type peptidase activity (GO:0008236)	8/125	3.30E-04	110.44	KLK1;KLK5;KLK4;KLK3;KLK15;KLK2;K LK8;KLK11
GO Molecular Function	thioesterase binding (GO:0031996)	2/11	0.049	166.1	CDC42;TRAF1
GO Biological Process	regulation of transcription by RNA polymerase II (GO:0006357)	36/2206	0.0064	28.19	EHF;NUCKS1;ZBTB4;ETS2;GLIS2;HOXA 10;POU5F1B;PGBD1;SDR16C5;HOXA9; ZNF827;SIX5;ZNF704;RUVBL1;ZKSCAN3 ;TRIM27;OTX1;SUDS3;ZBTB7B;ZNF367; E2F7;NKX3-1;MYOCD;NKX2- 6;BCL11A;ZBTB38;HMGA1;HNF1B;TBX3 ;DMRTA2;TFAP4;MAFF;MKX;TP53;TLR 4;FGFR2
GO Biological	regulation of transcription,	38/2244	0.0028	33.66	EHF;NUCKS1;PBXIP1;ZBTB4;ETS2;GLIS

Process	DNA-templated (GO:0006355)				2;HOXA10;POU5F1B;PGBD1;HOXA9;SI X5;ZNF704;RUVBL1;ZKSCAN3;GPBP1L1;OTX1;SUDS3;ZBTB7B;JARID2;ZNF367; E2F7;NKX3-1;MYOCD;NKX2- 6;BCL11A;ZBTB38;SETDB2;HMGA1;HN F1B;TBX3;GDF7;DMRTA2;TFAP4;MAFF;NAA16;MKX;TP53;PHF19
GO Biological Process	positive regulation of transcription, DNA- templated (GO:0045893)	22/1183	0.027	24.05	EHF;MYOCD;NKX2- 6;ZBTB38;HMGA1;HNF1B;ETS2;TBX3;G LIS2;GDF7;HOXA10;TFAP4;ZNF827;MA FF;ZKSCAN3;NAA16;OTX1;TP53;TLR4;F GFR2;E2F7;NKX3-1
GO Biological Process	positive regulation of transcription by RNA polymerase II (GO:0045944)	18/908	0.032	23.3	EHF;MYOCD;NKX2- 6;ZBTB38;HMGA1;HNF1B;TBX3;GLIS2; HOXA10;TERT;ZNF827;MAFF;OTX1;TP5 3;TLR4;FGFR2;E2F7;NKX3-1
GO Biological Process	negative regulation of transcription, DNA- templated (GO:0045892)	20/948	0.018	30.19	BCL11A;ZBTB38;SETDB2;HMGA1;PBXIP 1;ZBTB4;ETS2;TBX3;GLIS2;SDR16C5;TF AP4;ZKSCAN3;TRIM27;SUDS3;ZBTB7B;J ARID2;TP53;FGFR2;E2F7;NKX3-1
GO Biological Process	negative regulation of cellular macromolecule biosynthetic process (GO:2000113)	13/547	0.041	26.39	ZBTB38;SETDB2;HMGA1;PBXIP1;ZBTB4;TBX3;GLIS2;TFAP4;ZKSCAN3;SUDS3;JARID2;TP53;NKX3-1
GO Biological Process	negative regulation of nucleic acid-templated transcription (GO:1903507)	13/464	0.021	37.74	ZBTB38;SETDB2;HMGA1;PBXIP1;ZBTB4;TBX3;GLIS2;TFAP4;ZKSCAN3;SUDS3;JARID2;TP53;NKX3-1
GO Biological Process	regulation of cyclin- dependent protein serine/threonine kinase activity (GO:0000079)	5/82	0.047	66.09	CCNA2;MYOCD;CDKN2C;TFAP4;CDK5 RAP1
GO Biological Process	cellular component disassembly (GO:0022411)	5/66	0.027	94.49	MMP7;KLK5;KLK4;KLK2;A2M
GO Biological Process	extracellular matrix disassembly (GO:0022617)	5/66	0.027	94.49	MMP7;KLK5;KLK4;KLK2;A2M
GO Biological Process	negative regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045736)	3/20	0.047	176.28	MYOCD;TFAP4;CDK5RAP1
GO Biological Process	regulation of systemic arterial blood pressure (GO:0003073)	3/16	0.032	251.29	KLK1;KLK3;KLK2
GO Molecular Function	RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977)	26/1359	6.82E-04	30.85	EHF;ZBTB4;ETS2;GLIS2;HOXA10;POU5 F1B;PGBD1;HOXA9;SIX5;ZNF704;ZKSC AN3;OTX1;ZBTB7B;ZNF367;E2F7;NKX3- 1;NKX2- 6;BCL11A;ZBTB38;HNF1B;TBX3;DMRTA 2;TFAP4;MAFF;MKX;TP53

Figure 1: Miami Plot for Whole Blood TWAS Analysis




Figure 2: Miami Plot for Prostate Tissue TWAS Analysis




Figure 3: Manhattan plot for cross-tissue analyses




Figure 4. Statistically significant genes overlapping across TWAS analyses.




Figure 5: GO term enrichment results from the cross-tissue TWAS.

